Document Detail


Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors.
MedLine Citation:
PMID:  17320518     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Increased endocannabinoid (EC) system activity promotes excessive food intake and obesity in animals and humans. The EC system regulates food intake and hedonic reward through central mechanisms located within the hypothalamus and limbic forebrain. In rodent models, cannabinoid1 (CB1) receptor blockade reduces appetite and weight and prevents obesity and insulin resistance. The EC system also regulates food intake and metabolic factors through peripheral CB1 receptors located at multiple sites throughout the body, including adipose tissue, skeletal muscle, liver, and the gastrointestinal (GI) tract. In rodent models, CB1 receptor antagonists act in the liver to decrease lipogenesis, act in the GI tract to increase satiety, and function in adipose tissue to normalize adiponectin levels and reduce fat storage. The CB1 receptor antagonist rimonabant has been shown to reduce food intake and improve metabolic parameters, such as insulin resistance and fatty liver, in animal models of obesity. In preliminary human studies, upregulation of the EC system has been linked to obesity through mechanisms that include high-fat diet, insulin resistance, and genetic malfunction of an EC inactivation enzyme. Evidence suggests that CB1 receptor blockade is a novel therapeutic strategy that addresses the underlying mechanisms of both obesity and cardiometabolic risk.
Authors:
Stephen C Woods
Related Documents :
10794958 - Leptin: an essential regulator of lipid metabolism.
17181138 - Discovery of n-[(1s,2s)-3-(4-chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-...
16499998 - Food neophobia in the context of a varied diet induced by a weight reduction program in...
6804218 - Gold thioglucose-induced hypothalamic damage, hyperphagia, and obesity: dependence on t...
22695968 - Food prices and poverty negatively affect micronutrient intakes in guatemala.
8789548 - Increased levels of hyaluronan and albumin after intestinal challenge in adult patients...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  The American journal of medicine     Volume:  120     ISSN:  1555-7162     ISO Abbreviation:  Am. J. Med.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-02-26     Completed Date:  2007-04-09     Revised Date:  2007-12-03    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S19-25     Citation Subset:  AIM; IM    
Affiliation:
Obesity Research Center at the University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA. steve.woods@uc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiovascular Diseases / physiopathology
Disease Models, Animal
Endocannabinoids / physiology*
Fatty Liver / physiopathology
Humans
Insulin Resistance / physiology
Obesity / physiopathology*
Receptor, Cannabinoid, CB1 / antagonists & inhibitors,  physiology*
Risk Factors
Grant Support
ID/Acronym/Agency:
DK17844/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Endocannabinoids; 0/Receptor, Cannabinoid, CB1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of card...
Next Document:  Therapeutic options for modifying cardiometabolic risk factors.